May 20, 2026 – TheNewswire - Toronto, Ontario, Canada - Neurothera Labs Inc. (TSXV: NTLX) (“Neurothera” or the “Company”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), announces that it has adopted a semi-annual financial reporting ("SAR") framework, effective immediately. This change is being made pursuant to the Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933").

 

CBO 51-933 allows eligible venture issuers to voluntarily move from a quarterly to a semi-annual financial reporting framework.

Transition Details – Neurothera’s fiscal year ends on December 31. Under the SAR framework, the Company will be exempt from filing interim financial reports and related Management Discussion & Analysis (“MD&A”) for its first and third quarters for so long as it continues to meet eligibility criteria under CBO 51-933.

By adopting the SAR, Neurothera aims to reduce the administrative and financial burden associated with quarterly reporting, allowing management to focus resources on advancement of different projects.

• Initial Interim Period: The Company will not file an interim report for the first quarter (Q1) ending March 31, 2026 and for the third quarter (Q3) ending September 30, 2026. 

• Ongoing Reporting: Neurothera will continue to file audited annual consolidated financial statements (due within 120 days of December 31, 2026), and six-month interim financial reports (due within 60 days of June 30). 

• Continued Disclosure: The Company remains committed to timely disclosure and will continue to report all material changes and significant developments as required under National Instrument 51-102. 

• Eligibility: Neurothera confirms it meets the pilot program's eligibility criteria, which includes being a venture issuer with annual revenues of less than$10 million and maintaining a clean 12-month continuous disclosure record. 

• Continued Participation: Should the Company cease to continue participating in the SAR Pilot Program, it will announce it in a future news release 

About Neurothera Labs Inc.

Neurothera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

For further information, please contact:

Michal Efraty IR Manager Neurothera Labs Inc.

Telephone: +972-3-7617108

Email: michal@efraty.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.